Table 3. Treatment-related adverse events occurred in ≥10% of patients who received neoadjuvant therapy.
| Adverse event | Patients (n=21), n (%) | ||
|---|---|---|---|
| Any grade | Grade 3 | Grade 4 | |
| Diarrhea | 21 (100.0) | 6 (28.6) | 0 |
| Neutrophil count decreased | 17 (81.0) | 6 (28.6) | 1 (4.8) |
| WBC count decreased | 17 (81.0) | 5 (23.8) | 0 |
| Hand and foot numbness | 17 (81.0) | 0 | 0 |
| Fatigue | 15 (71.4) | 0 | 0 |
| Vomiting | 14 (66.7) | 2 (9.5) | 0 |
| Rash | 12 (57.1) | 0 | 0 |
| Nausea | 11 (52.4) | 0 | 0 |
| Positive fecal occult blood test | 10 (47.6) | 0 | 0 |
| ALT increased | 9 (42.9) | 0 | 0 |
| AST increased | 9 (42.9) | 0 | 0 |
| Oral mucositis | 9 (42.9) | 0 | 0 |
| Anemia | 8 (38.1) | 0 | 0 |
| Hand-foot syndrome | 6 (28.6) | 0 | 0 |
| Loss of appetite | 5 (23.8) | 0 | 0 |
| Blood bilirubin increased | 4 (19.0) | 0 | 0 |
| Creatinine increased | 4 (19.0) | 0 | 0 |
| Flatulence | 4 (19.0) | 0 | 0 |
| Nasal mucosa bleeding | 4 (19.0) | 0 | 0 |
| Skin pruritus | 3 (14.3) | 0 | 0 |
| Stomachache | 3 (14.3) | 0 | 0 |
WBC, white blood cell; ALT, alanine transaminase; AST, aspartate transaminase.